Fralin Biomedical Research Institute: Testing for Residual Cancer Cells Before Blood Cell Transplant Therapy is Important and Practical, New Study Finds
May 03, 2024
May 03, 2024
ROANOKE, Virginia, May 3 (TNSres) -- The Fralin Biomedical Research Institute at Virginia Tech issued the following news:
* * *
Research published in JAMA Oncology highlights the feasibility of testing for lingering cancer cells for patients in remission from a high-risk blood cancer, says Fralin Biomedical Research Institute at VTC Professor Christopher Hourigan.
* * *
By John Pastor
Patients in remission after battling a high-ris . . .
* * *
Research published in JAMA Oncology highlights the feasibility of testing for lingering cancer cells for patients in remission from a high-risk blood cancer, says Fralin Biomedical Research Institute at VTC Professor Christopher Hourigan.
* * *
By John Pastor
Patients in remission after battling a high-ris . . .